)
)
)
Branch Therapeutics
Branch Therapeutics is a 2024 founded oncology company developing first in class, orally administered multi kinase inhibitors to extend responses and delay relapse in solid tumors. Our lead series is unique among Wnt pathway regulators and targets Wnt driven stemness, PI3K alpha gain of function signaling, and type III receptor tyrosine kinases such as PDGFR in a single molecule, with high maximum tolerated doses and combination activity with current standards of care in preclinical models. This biology is shared by large patient segments across colorectal cancer, glioblastoma, hepatocellular carcinoma, and gastric adenocarcinoma. Branch completed a $4M Seed Round in 2025 to initiate operations. We will be at BioPartnering to seek meetings with pharma groups interested in partnering early and with investors who want an introduction now in view of our next financing round, anticipated to launch in 3Q2026.
Address
HoustonTexas
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)